Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases

Annals of the Rheumatic Diseases

Volumn 75, Issue 4, 2016, Pages 696-701

  Herbert, Megan K ^a   Stammen Vogelzangs, Judith ^a   Verbeek, Marcel M ^b,c   Rietveld, Anke ^b   Lundberg, Ingrid E ^d   Chinoy, Hector ^e   Lamb, Janine A ^e   Cooper, Robert G ^f   Roberts, Mark ^g   Badrising, Umesh A ^h   De Bleecker, Jan L ⁱ   Machado, Pedro M ^j   Hanna, Michael G ^j   Plestilova, Lenka ^k   Vencovsky, Jiri ^k   Van Engelen, Baziel G ^b   Pruijn, Ger J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSOLIC 5' NUCLEOTIDASE 1A ANTIBODY; ENZYME ANTIBODY; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; AUTOANTIBODY; NT5C1A PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CONTROLLED STUDY; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; COMPARATIVE STUDY; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYOSITIS, INCLUSION BODY; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

5'-NUCLEOTIDASE; ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; DERMATOMYOSITIS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR DISEASES; POLYMYOSITIS; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME;

EID: 84930014705     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206691     Document Type: Article

References (27)

1. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83-105.
2. Lazarou IN, Guerne P-A. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013;40:550-64.
3. Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013;15:1-10.
4. Hengstman GJD, Brouwer R, Vree Egberts WTM, et al. Clinical and serological characteristics of 125 Dutch myositis patients. J Neurol 2002;249:69-75.
5. Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.
6. Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-18.
7. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011;134:3167-75.
8. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84.
9. Badrising UA, Maat-Schieman MLC, Houwelingen JC, et al. Inclusion body myositis. J Neurol 2005;252:1448-54.
10. Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013;15:1-6.
11. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep 2012;13:321.
12. Askanas VMDP, Engel WKMD, Nogalska AP. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012;71:680-93.
13. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010;23:482-8.
14. Abdo W, Mierlo T, Hengstman G, et al. Increased plasma amyloid-ß42 protein in sporadic inclusion body myositis. Acta Neuropathol 2009;118:429-31.
15. Hiniker A, Daniels B, Lee H, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Comm. 2013;1:29.
16. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006;66:S33-8.
17. Badrising UA, Schreuder GMT, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63:2396-8.
18. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31.
19. Rojana-Udomsart A, Bundell C, James I, et al. Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): A population control study. J Neuroimmunol 2012;249:66-70.
20. Hunsucker SA, Spychala J, Mitchell BS. Human Cytosolic 5'-Nucleotidase I: Characterization and role in nucleoside analog resistance. J Biol Chem 2001;276:10498-504.
21. Lechward K, Tkacz-Stachowska K. Expression of cytosolic 5' nucleotidase does not correlate with expression of oxidative metabolism marker: myoglobine in human skeletal muscles. Acta Biochim Biophys Sin 2009;41:280-4.
22. Verschuuren JJ, Badrising UA, Wintzen AR, et al. Inclusion body myositis. In: Emery AEH, ed. Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine Press, 1997:81-4.
23. Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromusc Dis 2010;20:414-21.
24. Hengstman GJD, van Brenk L, Vree Egberts WTM, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005;252:534-7.
25. Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sjögren's syndrome associated with inclusion body myositis. Rheumatology 2002;41:440-4.
26. Rojana-Udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion body myositis and Sjögren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011;113:559-63.
27. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011;6:e20266.